Urol. praxi. 2024;25(4):233-236 | DOI: 10.36290/uro.2024.079

Retroperitoneal leiomyosarcoma

MUDr. Hana Dittrichová, MUDr. Pavel Hanek, MUDr. Klára Havlová
Urologické oddělení Oblastní nemocnice Příbram, a. s.

We describe a case report of a 69-year-old male with suspicious 30 mm mass in the area of left adrenal gland detected on ultrasound examination. Based on imaging examinations it was not possible to rule out a malignant potential of the lesion. The patient underwent left side adrenalectomy, the histological examination revealed a moderately differentiated, well-circumscribed leiomyosarcom. The adrenal gland was without infiltration. There were no signs of metastatic disease. According to the recommendation of multidisciplinary oncology team, he is placed under surveillance. The patient underwent a follow-up restaging CT 6 months after the surgery with negative results.

Keywords: retroperitoneal leiomyosarcoma, retroperitoneal tumors, soft tissue sarcoma.

Accepted: November 11, 2024; Published: November 25, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dittrichová H, Hanek P, Havlová K. Retroperitoneal leiomyosarcoma. Urol. praxi. 2024;25(4):233-236. doi: 10.36290/uro.2024.079.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 25.11.2025

    References

    1. Lischke R, Tomáš T, Kopečková K, et al. Sarkomy měkkých tkání - diagnostika a léčba: adoptovaný doporučený postup ESMO-EURACAN z roku 2018 pro diagnostiku, léčbu a následnou péči u pacientů s měkkotkáňovými a viscerálními sarkomy. Adoptovaný doporučený postup ESMO-EURACAN z roku 2018 pro diagnostiku léčbu a následnou péči u pacientů s gastrointestinálními stromálními tumory [Internet]. Národní portál klinických doporučených postupů; 2021 [cited 2024 Jan 08]. Available from: https://kdp.uzis.cz/res/guideline/14-sarkomy-mekkych-tkani-diagnostika-lecba-final.pdf
    2. Büchler T. Zhoubné nádory pojivové tkáně. In: Büchler T., et al. Speciální onkologie. Praha: Maxdorf; 2017. p. 141-149.
    3. Mota MMDS, Bezerra ROF, Garcia MRT. Practical approach to primary retroperitoneal masses in adults. Radiol Bras. 2018;51(6):391-400. Go to original source... Go to PubMed...
    4. Strauss DC, Hayes AJ, Thomas JM. Retroperitoneal tumours: review of management. Ann R Coll Surg Engl. 2011;93(4): 275-280. Go to original source... Go to PubMed...
    5. Choi JH, Ro JY. Retroperitoneal Sarcomas: An Update on the Diagnostic Pathology Approach. Diagnostics (Basel). 2020;10(9):642. Go to original source... Go to PubMed...
    6. Cormier JN, Pollock R. Soft tissue sarcomas. CA Cancer J. Clin. 2004;54(2):94-109. Go to original source... Go to PubMed...
    7. Mack T, Purgina B. Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma. Curr Oncol. 2022;29(9):6400-6418. Go to original source... Go to PubMed...
    8. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(11):1348-1365. Go to original source... Go to PubMed...
    9. Van Roggen JF, Hogendoorn PC. Soft tissue tumours of the retroperitoneum. Sarcoma. 2000;4(1-2):17-26. Go to original source... Go to PubMed...
    10. Schmitz E, Nessim C. Retroperitoneal Sarcoma Care in 2021. Cancers. 2022;14(5):1293. Go to original source... Go to PubMed...
    11. von Mehren M, Kane JM, Agulnik M, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815-833. Go to original source... Go to PubMed...
    12. Raval B; Pollock RE, Guadagnolo A, Patel S. Primary Retroperitoneal Tumors. [Internet]. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier; 2012, p. 403. [cited 2024 Jan 08]. Available from: https://www.sciencedirect.com/sdfe/pdf/download/eid/3-s2.0-B9781437722321000231/first-page-pdf Go to original source...
    13. Sassa N. Retroperitoneal tumors: Review of diagnosis and management. Int. J. Urol. 2020;27(12):1058-1070. Go to original source... Go to PubMed...
    14. Dominguez DA, Sampath S, Agulnik M, et al. Surgical Management of Retroperitoneal Sarcoma. Curr Oncol. 2023;30(5):4618-4631. Go to original source... Go to PubMed...
    15. Kiss I, et al. Zhoubný novotvar měkkých tkání (C38, 47-49). In: Modrá kniha České onkologické společnosti. KAPCZ, s.r.o.; 2023. p. 95-98.
    16. Marko J, Wolfman DJ. Retroperitoneal Leiomyosarcoma From the Radiologic Pathology Archives. Radiographics. 2018;38(5):1403-1420. Go to original source... Go to PubMed...
    17. Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29(4):857-871. Go to original source... Go to PubMed...
    18. Votrient [Internet]. European Medicines Agency. [Cited 2024 Jan 08]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/votrient.
    19. Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;4:16:1-10. Go to original source... Go to PubMed...
    20. Cranmer LD, Loggers ET, Pollack SM. Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag. 2016:12:941-955. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.